A shot twice a year reaches people daily pills never could
In South Africa, a country that has long carried one of the world's heaviest HIV burdens, a new twice-yearly injection called lenacapavir has begun to reach patients — offering a rare simplification in the long struggle against transmission. Where daily pills once demanded unbroken discipline from the most vulnerable, two annual shots promise a quieter, more forgiving form of protection. Yet this medical advance arrives at a moment of institutional retreat: American funding for global HIV programs is contracting, and the drug's global supply has not grown fast enough to meet the scale of need. Whether lenacapavir becomes a turning point or a missed opportunity will depend less on science than on the choices nations make about solidarity.
- A twice-yearly HIV prevention injection has begun rolling out in South Africa, offering a profound reduction in the daily burden that has long made prevention difficult for the most at-risk populations.
- U.S. aid cuts are already eroding the funding streams that have sustained South Africa's HIV infrastructure, threatening to hollow out the very system meant to deliver this new tool.
- Global manufacturing of lenacapavir has not scaled to meet demand, meaning doses are scarce and South Africa faces hard choices about who receives protection and who waits.
- Without equitable distribution, the drug risks flowing toward private clinics and away from rural, low-income, and marginalized communities — the populations it was most designed to reach.
- The rollout continues, but its transformative potential hangs on whether international donors hold their commitments and whether production lines can expand before the window of opportunity narrows.
South Africa has begun administering lenacapavir, a twice-yearly HIV prevention injection that marks a genuine departure from the daily pill regimens that have long defined prevention efforts. The shift matters because daily adherence is hardest for those most at risk — the poorest, the most marginalized, those whose lives offer little room for routine. Two shots a year, delivered at a clinic, removes that friction entirely. For a country where young women, sex workers, and rural communities continue to face high transmission rates despite decades of progress, this represents a meaningful new tool.
But the rollout is already under pressure from two directions. The United States is pulling back from global HIV funding, cutting into the financial architecture that South Africa's prevention programs depend on. At the same time, global manufacturing of lenacapavir has not kept pace with demand — the drug is new, production is limited, and doses are scarce. South Africa will have to make difficult decisions about allocation.
Those constraints carry real consequences. If supply stays tight and funding shrinks, lenacapavir could become a resource for those with access to private care rather than a population-wide intervention. The communities most exposed to HIV — those already underserved by the health system — risk being left at the back of the line. The drug itself has proven its value. What remains unproven is whether the international community will provide the resources, and the will, to let it reach the people who need it most.
South Africa is beginning to roll out lenacapavir, a twice-yearly injection that represents a significant shift in how the country might prevent HIV transmission. The drug requires only two shots per year—a stark departure from the daily pill regimen that has long been the standard for prevention. In a nation where HIV remains deeply embedded in the public health landscape, this new tool arrives with genuine promise. But the rollout is already shadowed by two converging threats: the United States is cutting funding for global HIV programs, and the global supply of lenacapavir remains constrained.
The significance of this injection lies partly in its simplicity. Daily medications demand adherence—taking a pill every single day, without fail, for months or years. That burden falls heaviest on the poorest and most vulnerable populations, the very people most at risk for HIV in South Africa. A twice-yearly shot removes that daily friction. A person can walk into a clinic twice a year and receive protection. For public health officials, this represents a potential breakthrough in reaching populations that daily pills have struggled to serve.
South Africa carries one of the world's highest HIV burdens. The country has made remarkable progress in recent decades—antiretroviral therapy has transformed HIV from a death sentence into a manageable chronic condition for millions. But prevention remains uneven. Young women, sex workers, and other marginalized groups continue to face high transmission rates. Lenacapavir offers a way to protect these populations before infection occurs, rather than treating them after.
Yet the promise collides with hard constraints. U.S. aid reductions are already cutting into the funding streams that have long supported South Africa's HIV programs. At the same time, global manufacturing capacity for lenacapavir has not kept pace with demand. The drug is new, the production lines are limited, and doses are scarce. South Africa will not have unlimited access to this tool. Decisions will have to be made about who gets the injections and who waits.
These bottlenecks matter because they determine whether lenacapavir becomes a transformative public health intervention or a limited resource available only to some. If supply remains tight and funding shrinks, the drug risks becoming a tool for those with access to private clinics rather than a population-wide prevention strategy. The populations most vulnerable to HIV—those in rural areas, those without stable income, those already marginalized by the health system—could be left behind.
The rollout is underway, but its trajectory remains uncertain. Success will depend on whether the United States and other donors sustain their commitment to global HIV prevention, whether manufacturers can scale up production, and whether South Africa can navigate the difficult work of equitable distribution. The drug itself is proven. The question now is whether the world will provide the resources and supply to let it do what it was designed to do.
The Hearth Conversation Another angle on the story
Why does a twice-yearly shot matter so much more than a daily pill?
Because adherence is the invisible killer in prevention. A pill you have to take every day is a pill that gets missed—life gets chaotic, people travel, clinics are far away. A shot twice a year is something you can plan for, something a clinic can remind you about. It's the difference between a tool that works in theory and one that actually reaches people.
And South Africa specifically—why is this rollout happening there first?
South Africa has the infrastructure, the HIV expertise, and the urgent need. They've been fighting this epidemic longer than almost anywhere else. They have the clinics, the trained workers, the data systems. But they also have the burden—millions of people at risk. It's the right place to test whether this works at scale.
What does a U.S. aid cut actually mean on the ground?
It means fewer doses purchased, fewer clinics equipped to administer them, fewer health workers trained. It means the people who get the shot are the ones closest to the system—not the ones furthest from it. The ones who need it most are the ones least likely to get it.
Is there a timeline for when supply might catch up?
Not a clear one. Manufacturing takes time. You can't just flip a switch and double production. And if funding is shrinking while demand is growing, you get a squeeze. That's where we are now.
What happens if this stays scarce?
Then it becomes a tool for inequality. The wealthy get protected. The vulnerable stay exposed. And the epidemic keeps moving through the populations that were always most at risk.